CA3144443A1 - Method of reconstituting liposomal annamycin - Google Patents

Method of reconstituting liposomal annamycin Download PDF

Info

Publication number
CA3144443A1
CA3144443A1 CA3144443A CA3144443A CA3144443A1 CA 3144443 A1 CA3144443 A1 CA 3144443A1 CA 3144443 A CA3144443 A CA 3144443A CA 3144443 A CA3144443 A CA 3144443A CA 3144443 A1 CA3144443 A1 CA 3144443A1
Authority
CA
Canada
Prior art keywords
annamycin
liposomal
saline
bag
vial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3144443A
Other languages
English (en)
French (fr)
Inventor
Donald Picker
Waldemar Priebe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Moleculin Biotech Inc
Original Assignee
University of Texas System
Moleculin Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, Moleculin Biotech Inc filed Critical University of Texas System
Publication of CA3144443A1 publication Critical patent/CA3144443A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
CA3144443A 2019-06-28 2020-06-25 Method of reconstituting liposomal annamycin Pending CA3144443A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962868190P 2019-06-28 2019-06-28
US62/868,190 2019-06-28
PCT/US2020/039621 WO2020264161A1 (en) 2019-06-28 2020-06-25 Method of reconstituting liposomal annamycin

Publications (1)

Publication Number Publication Date
CA3144443A1 true CA3144443A1 (en) 2020-12-30

Family

ID=74061076

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3144443A Pending CA3144443A1 (en) 2019-06-28 2020-06-25 Method of reconstituting liposomal annamycin

Country Status (15)

Country Link
US (2) US12257262B2 (https=)
EP (1) EP3990041B1 (https=)
JP (1) JP7830131B2 (https=)
KR (1) KR20220027941A (https=)
CN (2) CN114728101B (https=)
AU (2) AU2020302784A1 (https=)
BR (1) BR112021026480A2 (https=)
CA (1) CA3144443A1 (https=)
ES (1) ES3049663T3 (https=)
IL (1) IL289433B1 (https=)
MX (1) MX2021015667A (https=)
PL (1) PL3990041T3 (https=)
SG (1) SG11202113005SA (https=)
TW (2) TWI857086B (https=)
WO (1) WO2020264161A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021015668A (es) 2019-06-28 2022-04-18 Univ Texas Preparacion de un liofilizado de anamicina preliposomica.
BR112021026480A2 (pt) 2019-06-28 2022-02-08 Univ Texas Método para reconstituir anamicina, método para preparar uma dose eficaz de uma formulação lipossômica reconstituída de anamicina e método para tratar câncer
EP4061810A4 (en) * 2019-11-21 2023-12-20 Board of Regents, The University of Texas System Lung targeted anticancer therapies with liposomal annamycin

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927571A (en) * 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US4863739A (en) 1987-05-19 1989-09-05 Board Of Regents, The University Of Texas System Liposome compositions of anthracycline derivatives
IS1685B (is) * 1990-12-11 1998-02-24 Bracco International B.V. Aðferð við að búa til fitukúlur (liposomes) sem eru gæddar auknum hæfileika til að draga í sig og halda í sér aðskotaefnum
US5902604A (en) * 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
WO2001032145A1 (en) 1999-10-29 2001-05-10 Board Of Regents, The University Of Texas System Method of cancer treatment
TWI433693B (zh) * 2003-02-14 2014-04-11 Childrens Hosp & Res Ct Oak 親脂藥物傳送媒介物及其使用方法
ES2637072T3 (es) * 2010-03-10 2017-10-10 Cempra Pharmaceuticals, Inc. Formulación parenteral de antibióticos macrólidos
IL301603A (en) * 2011-10-14 2023-05-01 Genentech Inc Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient
SI2768484T1 (sl) * 2011-10-21 2019-12-31 Jazz Pharmaceuticals Research Llc Liofilizirani liposomi
US8926994B2 (en) 2011-12-07 2015-01-06 The Methodist Hospital Research Institute Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
CN107569508A (zh) * 2016-07-05 2018-01-12 江苏竞诺择生物医药科技有限公司 一种治疗造血系统增殖性疾病的药用组合物
KR20190067172A (ko) 2016-09-09 2019-06-14 아이리시스, 인크. 리포좀 항암 조성물
WO2019023873A1 (zh) * 2017-07-31 2019-02-07 江苏竞诺择生物医药科技有限公司 一种用于治疗造血系统增殖性疾病的纳米脂质微粒组合物及药用组合物
CN112955145A (zh) 2018-09-04 2021-06-11 密涅瓦神经科学有限公司 使用苯氧丙胺化合物治疗疼痛的方法
BR112021026480A2 (pt) 2019-06-28 2022-02-08 Univ Texas Método para reconstituir anamicina, método para preparar uma dose eficaz de uma formulação lipossômica reconstituída de anamicina e método para tratar câncer
MX2021015668A (es) 2019-06-28 2022-04-18 Univ Texas Preparacion de un liofilizado de anamicina preliposomica.
EP4061810A4 (en) 2019-11-21 2023-12-20 Board of Regents, The University of Texas System Lung targeted anticancer therapies with liposomal annamycin

Also Published As

Publication number Publication date
KR20220027941A (ko) 2022-03-08
AU2024203593A1 (en) 2024-07-11
ES3049663T3 (en) 2025-12-17
AU2024203593B2 (en) 2025-08-14
EP3990041B1 (en) 2025-08-06
IL289433B1 (en) 2026-01-01
US11980634B2 (en) 2024-05-14
US20220105116A1 (en) 2022-04-07
CN114728101A (zh) 2022-07-08
TWI857086B (zh) 2024-10-01
CN114728101B (zh) 2023-07-14
SG11202113005SA (en) 2021-12-30
EP3990041A4 (en) 2023-07-12
WO2020264161A1 (en) 2020-12-30
TW202114704A (zh) 2021-04-16
TW202500161A (zh) 2025-01-01
MX2021015667A (es) 2022-04-18
US20240024345A1 (en) 2024-01-25
PL3990041T3 (pl) 2026-02-23
CN116785242A (zh) 2023-09-22
JP2023523872A (ja) 2023-06-08
JP7830131B2 (ja) 2026-03-16
US12257262B2 (en) 2025-03-25
IL289433A (en) 2022-02-01
EP3990041A1 (en) 2022-05-04
BR112021026480A2 (pt) 2022-02-08
AU2020302784A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
US11980634B2 (en) Method of reconstituting liposomal annamycin
KR101495951B1 (ko) 리포솜 조성물
AU2024203598A1 (en) Preparation of preliposomal annamycin lyophilizate
HK40073244A (en) Method of reconstituting liposomal annamycin
HK40073244B (en) Method of reconstituting liposomal annamycin
AU2020303572B2 (en) Preparation of preliposomal Annamycin lyophilizate
AU2014200717B2 (en) Liposome composition
CA3142510C (en) Preparation of preliposomal annamycin lyophilizate
CN114712309B (zh) 一种人参皂苷多西他赛脂质体、其制备方法和应用

Legal Events

Date Code Title Description
D17 Fast track examination accepted

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D17-D110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION DETERMINED COMPLIANT - PARAGRAPH 84(1)(A) OF THE PATENT RULES

Effective date: 20240702

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20240702

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240814

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241122

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250130

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250204

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250204

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250620

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250620

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250630

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251002

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251203

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251203

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260213

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260216